title: Effects of morin-5'-sulfonic acid sodium salt (NaMSA) on cyclophosphamide-induced changes in oxido-redox state in rat liver and kidney.
abstract: Cyclophosphamide (CPX) is an anticancer drug with immunosuppressive properties. Its adverse effects are partly connected to the induction of oxidative stress. Some studies indicate that water-soluble derivative of morin-morin-5'-sulfonic acid sodium salt (NaMSA) exhibits strong antioxidant activity. The aim of present study was to evaluate the effect of NaMSA on CPX-induced changes in oxido-redox state in rat. Experiment was carried out on Wistar rats divided in three experimental groups (N = 12) receiving: 0.9% saline, CPX (15 mg/kg) or CPX (15 mg/kg) + NaMSA (100 mg/kg), respectively, and were given intragastrically for 10 days. Malondialdehyde (MDA) and glutathione (GSH) concentrations and superoxide dismutase (SOD) activity were determined in liver and kidneys. Catalase (CAT) activity was assessed only in liver. Treatment with CPX resulted in significant decrease in MDA level in both tissues, which was completely reversed by NaMSA treatment only in liver. In comparison to the control group significant decrease in SOD activity were observed in both tissues of CPX receiving group. In kidneys this parameter was fully restored by NaMSA administration. CPX evoked significant decrease in GSH concentration in kidneys, which was completely reversed by NaMSA treatment. No significant changes were seen in GSH levels and CAT activity between all groups in liver. Results of our study suggest that CPX may exert significant impact on oxido-redox state in both organs. NaMSA fully reversed the CPX-induced changes, especially MDA level in liver, SOD activity and GSH concentration in kidneys and it may be done by enhancement of activity/concentration of endogenous antioxidants.
authors.affiliation: Department of Pharmacology, Wroclaw Medical University, Wrocław, Poland. amerwid@mp.pl
authors.forename: A
authors.initials: A
authors.lastname: Merwid-Ląd
authors.forename: M
authors.initials: M
authors.lastname: Trocha
authors.forename: E
authors.initials: E
authors.lastname: Chlebda
authors.forename: T
authors.initials: T
authors.lastname: Sozański
authors.forename: J
authors.initials: J
authors.lastname: Magdalan
authors.forename: D
authors.initials: D
authors.lastname: Ksiądzyna
authors.forename: M
authors.initials: M
authors.lastname: Kopacz
authors.forename: A
authors.initials: A
authors.lastname: Kuźniar
authors.forename: D
authors.initials: D
authors.lastname: Nowak
authors.forename: M
authors.initials: M
authors.lastname: Pieśniewska
authors.forename: L
authors.initials: L
authors.lastname: Fereniec-Gołębiewska
authors.forename: J
authors.initials: J
authors.lastname: Kwiatkowska
authors.forename: A
authors.initials: A
authors.lastname: Szeląg
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents; D000975:Antioxidants / Q000494:pharmacology*; D002374:Catalase / Q000378:metabolism; D003520:Cyclophosphamide; D005260:Female; D005419:Flavonoids / Q000494:pharmacology*; D005978:Glutathione / Q000378:metabolism; D007166:Immunosuppressive Agents; D007668:Kidney / Q000187:drug effects* / Q000378:metabolism; D008099:Liver / Q000187:drug effects* / Q000378:metabolism; D008297:Male; D008315:Malondialdehyde / Q000378:metabolism; D010084:Oxidation-Reduction; D018384:Oxidative Stress / Q000187:drug effects*; D051381:Rats; D017208:Rats, Wistar; D013451:Sulfonic Acids / Q000494:pharmacology*; D013482:Superoxide Dismutase / Q000378:metabolism
chemical_list: D000970:Antineoplastic Agents; D000975:Antioxidants; D005419:Flavonoids; D007166:Immunosuppressive Agents; D013451:Sulfonic Acids; C576986:morin-5'-sulfonic acid; D008315:Malondialdehyde; D003520:Cyclophosphamide; D002374:Catalase; D013482:Superoxide Dismutase; D005978:Glutathione